NCT01117857

Duloxetine for Menopausal Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: Female
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to determine if an eight-week intervention with duloxetine significantly reduces depressive symptoms in symptomatic menopausal women. It is hypothesized that an eight-week trial with duloxetine promotes significant improvement in depression symptoms in menopausal women. The secondary aim of the study is to examine if an eight-week intervention with duloxetine significantly reduces vasomotor symptoms in symptomatic menopausal women. It is hypothesized that an eight-week trial with duloxetine promotes significant improvement in vasomotor symptoms in menopausal women.

Conditions

• Depression
• Menopause
• Vasomotor Symptoms

Interventions

Type	Name	Description
DRUG	Duloxetine	One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-05-06
• Last updated: 2014-08-21
• Results posted: 2014-08-21

Locations

1 site across 1 country: United States